-
Mashup Score: 0
Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous familial hypercholesterolemia in children aged 5 to 11 years.After priority review by the FDA, evinacumab-dgnb (Evkeeza) is the first angiopoietin-like 3 inhibitor treatment to be indicated for children as young as 5 years old to treat
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ACC Online Courses - American College of Cardiology - 1 year(s) ago
Find information and links to ACC Online Courses on this page.
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Healthy lifestyle can cut CVD risk in patients with FH - 1 year(s) ago
A healthy lifestyle was associated with reduced risk for CVD among adults with familial hypercholesterolemia regardless of their familial hypercholesterolemia mutation status, researchers reported.βDNA is not destiny; it is not deterministic for familial hypercholesterolemia (FH),β Hayato Tada, MD, PhD, assistant professor in the department of cardiovascular medicine at Kanazawa
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patients with familial hypercholesterolemia may be more vulnerable to eating disorders - 1 year(s) ago
A study published in the European Journal of Preventive Cardiology found that patients with familial hypercholesterolemia may have elevated risk for developing eating disorders. βNo previous studies have investigated risk of [eating disorders] in individuals with FH. The purpose of this study was therefore to investigate if individuals with genetically verified FH, who are likely to have
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Long-term PCSK9 inhibition plus background therapy improves LDL goal attainment in FH - 1 year(s) ago
Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported. This long-term prospective analysis of the Spanish Familial Hypercholesterolemia Cohort Study (SAFEHEART) was published in the European Journal of Preventive Cardiology.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
We are grateful to these distinguished faculty who contributed to this collection: Michael D. Shapiro, DO, FACC (Chair) Charles German, MD, MS Christie M. Ballantyne, MD, FACC Pam Taub, MD, FACCΒ Raul D. Santos MD, PhD, MSc Salim S. Virani, MD, FACC Sarah de Ferranti MD, MPH
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7
Regeneron Pharmaceuticals
Source: CardioSmartCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0A Botched Cancer Test, a National Scandal, and an Irish Hero - 1 year(s) ago
Ireland is mourning Vicky Phelan, who died this week. She became an advocate for women after a Pap smear that had been deemed negative turned out to be positive.
Source: www.nytimes.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Xyleme Syndicate Portal - 1 year(s) ago
{{‘document.preview.not.available’ | i18n}} {{‘document.preview.open.in.new.window’ | i18n}} {{‘document.preview.click.in.new.window’ | i18n}} {{ coreErrorMessage ? coreErrorMessage : (‘share.preview.error.403’ | i18n) }} {{ coreErrorMessage ? coreErrorMessage : (‘share.preview.error.404’…
Source: acc.bravais.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Familial hypercholesterolemia in 9% of young adults with ACS; many undertreated afterward - 2 year(s) ago
Among younger patients with ACS, approximately one in 11 had familial hypercholesterolemia, researchers reported in The American Journal of Cardiology. Among those with familial hypercholesterolemia (FH), fewer than half were treated with ezetimibe and/or PCSK9 inhibitors after their ACS event, according to the researchers.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
Regeneron announced the FDA has extended approval of #evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous #FamilialHypercholesterolemia in children aged 5 to 11 years @US_FDA @EndocrineToday #Cardiotwitter https://t.co/Mloyd8ZD6v